Literature DB >> 6397501

Aldosterone and plasma renin activity in hyperthyroid rats: effects of propranolol and propylthiouracil.

M Montiel, E Jiménez, J A Naváez, M Morell.   

Abstract

Variations in renin- angiotensin-aldosterone system (RAAS) in experimentally induced hyperthyroidism were studied. The changes observed in the RAAS in these conditions, evaluated through the plasma renin activity (PRA), are parallel to serum aldosterone concentration (AC). An increase in PRA and AC is produced following the administration of triiodothyronine, possibly through elevated adrenergic activity: beta-blocker, propranolol, returned the PRA and AC to normal. The active hormone is seen to be triiodothyronine, confirmed by using the antithyroid preparation, propylthiouracil, to inhibit the conversion of thyroxine. Propylthiouracil administration to hyperthyroid animals lowers the PRA and AC.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6397501     DOI： 10.1007/BF03349486

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  15 in total

1.  ALDOSTERONE SECRETION AND METABOLISM IN HYPERTHYROIDISM AND MYXEDEMA.

Authors:  J A LUETSCHER; A P COHN; C A CAMARGO; A J DOWDY; A M CALLAGHAN
Journal:  J Clin Endocrinol Metab       Date:  1963-09       Impact factor: 5.958

2.  Loci of action of regulators of aldosterone biosynthesis in isolated glomerulosa cells.

Authors:  G Aguilera; K J Catt
Journal:  Endocrinology       Date:  1979-04       Impact factor: 4.736

3.  A non-chromatographic non-extraction radioimmunoassay for serum aldosterone.

Authors:  T Ogihara; K Iinuma; K Nishi; Y Arakawa; A Takagi
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

4.  Control of aldosterone secretion in hyperthyroidism.

Authors:  J P Cain; R G Dluhy; G H Williams; H A Selenkow; A Milech; S Richmond
Journal:  J Clin Endocrinol Metab       Date:  1973-02       Impact factor: 5.958

5.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

6.  Elevation of serum potassium during beta blockade: absence of relationship to the renin-aldosterone system.

Authors:  Y M Traub; M Rabinov; J B Rosenfeld; S Treuherz
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

7.  Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension.

Authors:  J I Drayer; P W Kloppenborg; J Festen; A van't Laar; T J Benraad
Journal:  Am J Cardiol       Date:  1975-10-31       Impact factor: 2.778

8.  Renin-angiotensin system in hypothyroid rats: effects of potassium iodide and triiodo-L-thyronine.

Authors:  E Jiménez; M Montiel; J A Narváez; M Morell
Journal:  Acta Endocrinol (Copenh)       Date:  1984-04

9.  Thyroid hormone levels after acute L-thyroxine loading in hypothyroidism.

Authors:  W A Valente; W H Goldiner; B P Hamilton; J G Wiswell; J H Mersey
Journal:  J Clin Endocrinol Metab       Date:  1981-09       Impact factor: 5.958

10.  Effects of hyper- and hypothyroidism on the basal levels of angiotensin I and kinetic parameters of renin-angiotensin system in male rats.

Authors:  E Jiménez; M Montiel; J A Narváez; M Morell
Journal:  Rev Esp Fisiol       Date:  1982-06
View more
  2 in total

1.  Angiotensin II AT1 receptor stimulates Na+ -K+ATPase activity through a pathway involving PKC-zeta in rat thyroid cells.

Authors:  S Marsigliante; A Muscella; M G Elia; S Greco; C Storelli
Journal:  J Physiol       Date:  2003-01-15       Impact factor: 5.182

2.  Prediction of response to medical therapy by serum soluble (pro)renin receptor levels in Graves' disease.

Authors:  Yuki Mizuguchi; Satoshi Morimoto; Shihori Kimura; Noriyoshi Takano; Kaoru Yamashita; Yasufumi Seki; Kanako Bokuda; Midori Yatabe; Junichi Yatabe; Daisuke Watanabe; Takashi Ando; Atsuhiro Ichihara
Journal:  PLoS One       Date:  2018-04-05       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.